NLRP3 and type 2 diabetes mellitus: For example, subjects with T2DM at high cardiovascular risk were given sulfonylurea or empagliflozin (SGLT2i) treatment for 30 days, and the activation of NLRP3 inflammasome in macrophages was analyzed.